Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
about
Why bortezomib cannot go with 'green'?Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and TherapyKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaPhase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophiesBTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in miceTreatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideRedox control of leukemia: from molecular mechanisms to therapeutic opportunities.The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccinationEmerging therapy for chronic lymphocytic leukaemia.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsUse of class I histone deacetylase inhibitor romidepsin in combination regimensA high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyTreatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.Targeted therapy in chronic lymphocytic leukemia: past, present, and future.The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells.NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia.NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.Bortezomib: friend or foe of hemolytic anemia?New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma.Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.Proteasome inhibitors in acute leukemia.B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.Apoptosis inducers in chronic lymphocytic leukemia.Chronic lymphocytic leukaemia genomics and the precision medicine era.Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cellsRelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.Adult-onset adrenoleukodystrophy presenting after chemotherapy: No black and white matter.Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.
P2860
Q24630709-9B502DA4-DA34-4560-B863-F59CF9460623Q26740191-4683C9D7-5E1C-4C87-AAA7-B52796457127Q26781895-16F5CF1A-6E8F-4D52-9EA3-4F4B64773D1EQ33420278-8EA4F8F6-8850-4EBB-9621-022DFF3DD4F5Q33745227-79C90B8E-BC15-4DE2-9485-DD7305EEE720Q34041311-8295E618-45E1-4876-AE14-DE2DF6E15F33Q35175035-E02D7A55-A7DC-47F1-8342-0EF97912BF39Q35755000-338BF4D5-2E20-4DFB-9EC4-C020BF3F9345Q35989980-727E1353-CF4F-4113-8754-B0092F236A0AQ36646486-05BE6638-5076-4270-AE15-512FF8858FE2Q36815262-9E05A7DD-4515-4384-9F7D-90CB131514A1Q36874310-4252DC2E-69E7-4451-B55C-98F8AC1361D6Q36981738-344013C7-32B5-47E3-BF3A-5A48E2650A1FQ37017342-2CEAC2D4-92DF-42E2-8DD9-6D7BAD758E94Q37107439-5BE05F60-5CA7-40A7-9D1C-6CDE5247C44EQ37112857-25C4F7BA-69E1-46BE-82F0-47EB66944748Q37233146-FFBB1C1F-C9AA-4235-995B-9A064CC068ECQ37318762-0A62E90D-9E27-4870-8B86-00E984BBEE64Q37427124-781C2E58-9CF7-4B35-B852-26659FBF9A15Q37430243-B192A29C-5875-43FE-876A-375AF118C119Q37564440-FFD7BB5F-81BB-406A-972F-D7933D89665EQ37605861-C37B30F0-4402-4BA2-95BA-970B292F646CQ37690750-2798B881-1C76-41CE-8BB8-480B675093D1Q37766378-A765E8FF-3EEE-4524-9F3E-74B1B9AC6EFAQ37786616-D248F086-A89C-4636-8F71-03B41F73C138Q37866334-B386E53F-0231-42C6-BD87-E3F00C3BA717Q37997623-5696CF52-ADB2-4FA5-94ED-B772A657EBB3Q38088003-8F5A3A2A-F3EA-437B-BBB5-033411E031B6Q38124119-29CDF8C6-CBAD-419B-80AA-23CDEF42F2E1Q38187815-EFC8981B-28A4-46F6-A015-09ABA7DD06BFQ39263974-408A5BA9-76C3-42FA-98EC-01B14C9E80EAQ39627475-8D03FE13-37BB-4903-B9DD-57A9BD4620EBQ39960462-5AFED5CC-0024-467D-9396-1022149D008EQ41915878-0BF6E4DE-607A-4268-8E8E-4210D87921C0Q42444933-D886F9A0-3C59-423D-86C7-6F8FD62D0488Q43285192-4133D4BD-E562-46D7-B6E5-F652D18E064BQ45172522-E9C0FF89-3B02-4288-B8DA-6269CE3E6F72Q46067297-94609458-B736-443D-A164-4C3746467835Q49444062-8004C3FF-5E3B-470F-80EE-D0E9084794F2Q50911306-EFA6812E-A6C7-4DD2-B671-0BBC93C2CB2F
P2860
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase II study of single-agent ...... chronic lymphocytic leukemia.
@ast
Phase II study of single-agent ...... chronic lymphocytic leukemia.
@en
type
label
Phase II study of single-agent ...... chronic lymphocytic leukemia.
@ast
Phase II study of single-agent ...... chronic lymphocytic leukemia.
@en
prefLabel
Phase II study of single-agent ...... chronic lymphocytic leukemia.
@ast
Phase II study of single-agent ...... chronic lymphocytic leukemia.
@en
P2093
P50
P356
P1433
P1476
Phase II study of single-agent ...... chronic lymphocytic leukemia.
@en
P2093
Dixie-Lee Esseltine
John Gribben
Shihong Sheng
P304
P356
10.1002/CNCR.22097
P407
P577
2006-09-01T00:00:00Z